Recommendation of the President – Keytruda (pembrolizumab)
On 16 December 2025. the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 194/2025 on the reimbursement of the medicinal product Keytruda (pembrolizumab) under the B.5 drug program. “Treatment of patients with hepatocellular carcinoma (ICD-10: C22.0) or bile duct cancer (ICD-10: C22.1, C23, C24.0, C24.1, C24.8, C24.9)”